Monograph Capital Partners — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Ollin Biosciences, Inc.May 2026
A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.
Austin, US
Board seatTravis Murdoch· per SEC Form D
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.